Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLECAINIDE ACETATE

All products: not a benefit

Other products in the same Health Canada class (C01B, C01BC) — coverage varies; not interchangeable

  • Propafenone (Rythmol): general benefit
  • Amiodarone (Cordarone): general benefit, Not a benefit
  • Disopyramide (Norpace): general benefit, Not a benefit, Listing status unconfirmed
  • Mexiletine (Mexitil): general benefit, Not a benefit

Tambocor · DIN 01966197 · 50mg · tablet

Listed, not a benefitDormant since 2021-03-03 · checked 2026-09-19 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tambocor · DIN 01966197 Manufacturer: Graceway Pharmaceuticals; listing date 1996-10-01 Health Canada: Dormant since 2021-03-03 · brand TAMBOCOR · ATC C01BC04 FLECAINIDE · form Tablet · route Oral · ingredients FLECAINIDE ACETATE 50 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Tambocor: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13513 · Verify on the e-Formulary ↗ (DIN 01966197)

Source record
DIN 01966197: Tambocor Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400119; group id 282; item number 0601; lccId None; manufacturer id GRA Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01966197 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13513
Interchangeable products
Apo-Flecainide · DIN 02275538 · $0.1389 Auro-Flecainide · DIN 02459957 · $0.1389 Flecainide · DIN 02534800 · $0.1389 Jamp Flecainide · DIN 02493705 · $0.1389 Mar-Flecainide · DIN 02476177 · $0.1389 NRA-Flecainide · DIN 02530066 · $0.1389
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since 2021-03-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

PROPAFENONE HCL

· 6 products · General benefit · strengths: 150mg, 300mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications In patients without structural heart disease and with disabling symptoms, APO-FLECAINIDE is indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal re-entrant tachycardia, atrioventricular re-entrant tachycardia and other supraventricular tachycardias of unspecified mechanism, • paroxysmal atrial fibrillation/flutter (PAF). Patients treated with APO-FLECAINIDE for supraventricular arrhythmias having impaired left ventricular function (ejection fraction < 40) and/or ischemic heart disease may be at increased risk for cardiac adverse reactions. Use of APO-FLECAINIDE in chronic atrial fibrillation has not been adequately studied and is not recommended (see 3 Serious Warnings and Precautions Box). APO-FLECAINIDE is also indicated for the treatment of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgement of the physician, are life-threatening. • Because of the proarrhythmic effects of APO-FLECAINIDE, its use should be reserved for patients in whom, in the opinion of the physician, the benefits… https://pdf.hres.ca/dpd_pm/00083156.PDF PM date: JAN 13, 2026 Source product: APO-FLECAINIDE; DIN 02275538; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Tambocor: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026